FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Tirzepatide, a GLP-1 medication already on the market to treat diabetes, is now FDA approved to help those suffering from ...

Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Once home, I was convinced I’d never sleep again for fear of more episodes of apnea. We purchased a specialized baby monitor ...

I asked Dr. Acostamadiedo what causes night terrors, hallucinations and other parasomnias, to get to the root of my recurring ...

For years, Michelle Strickland had trouble sleeping – she woke up several times at night – and it left her with daytime sleepiness and her body craving lots of naps. Strickland recently went ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

To Know in detail about the Obstructive Sleep Apnea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obstructive Sleep Apnea Market Forecast Some of the key ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.